Abstract
Levonorgestrel (Norplant, Wyeth–Ayerst Laboratories, Philadelphia) is a subdermally implanted synthetic progestin that has been available in the United States since 1991. Intracranial hypertension developed in two women seen at the Oregon Health Sciences University after the insertion of this implant. We reviewed data from the national Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oreg.), the Food and Drug Administration's Spontaneous Reporting System (Rockville, Md.), and the World Health Organization's Collaborating Center for International Drug Monitoring (Uppsala, Sweden) for a possible association between levonorgestrel use and intracranial hypertension. A total of 56 cases of intracranial hypertension or disk edema were found. Most cases were reported by physicians who believed the events may have been drug-related. The patients were female, with a mean age of 22 years (range, 16 to 34), and they had been treated with levonorgestrel for a mean of 206 days (range, 9 to 616) before the onset of the syndrome. We have no data about the weight of these women. Visual-field defects were reported in seven patients, and diplopia in six. Levonorgestrel has been associated with intracranial hypertension in two other patients.1

This publication has 3 references indexed in Scilit: